Akut Myeloid Lösemide CD11b İfadesinin Hemostatik Komplikasyonlar ve Tedaviye Yanıt ile İlişkisi

Year 2020, Volume: 8 Issue: 1, 16 - 21, 20.04.2020

Mehmet Baysal , Elif G Ümit Gökhan Öztürk Sedanur Karaman Gülsaran Volkan Baş Onur Kırkızlar , Ahmet Muzaffer Demir

https://doi.org/10.37696/nkmj.603530

Abstract

Amaç:
Çalışmamızda, Akut Myeloid Lösemi (AML) hastalarında CD11b ekspresyonunun klinik
seyir ve hastalığın prognozu üzerine etkilerini araştırmayı amaçladık.

Gereç ve yöntem:
Trakya bölgesindeki bir üçüncü  basamak
hastane olan Trakya Üniversitesi Tıp Fakültesi, Hematoloji Anabilim Dalı'nda 2014-2017
yılları arasında, Dünya Sağlık Örgütü 2016 myeloid maligniteler sınıflamasına
göre AML tanısı almış 123 hastanın verileri retrospektif olarak değerlendirildi.

Bulgular:
Çalışmamızdaki 123 hastanın 60'ı kadın, 63'ü erkekti. Yaş ortalaması 57.93 idi.
CD11b pozitifliği 40 hastada gözlendi. CD 11b pozitifliği olan hastalarda
trombosit sayısı anlamlı derecede düşüktü (p = 0.004). Aynı şekilde, D-dimer
düzeyleri de CD11b pozitif hasta grubunda daha yüksekti (p = 0.000). Sonuçlar
ile ilgili olarak, CD 11b pozitifliği olan hastalarda ilk remisyon indüksiyon
tedavisi ile remisyon oranlarının daha düşük olduğu bulundu (p = 0.003). Kaplan
Meier sağkalım analizinde; CD-11b pozitifliği ile genel sağkalım arasında bir
ilişki bulunamadı (CD 11b pozitif grupta 8.5 ay, negatif grupta 12.1 ay, p:
0.436).

Sonuç:
Çalışmamız CD11b ifadesi olan hastaların remisyon indüksiyon kemoterapisi ile
daha düşük remisyon oranlarına sahip olduğunu göstermiştir. CD11b, lösemik hücrelerin
kemik iliği mikroçevresindeki etkileşimi için gereklidir. CD11b ifadesi AML
hastalarında immün kaçış mekanizmalarının bir parçası olabilir.

Keywords

Akut Miyeloid Lösemi, CD11b, Akım Sitometri

CD11b Expression in Acute Myeloid Leukemia is Associated with Hemostatic Complications and Response to Treatment

Abstract

Objective: In
our study, we aimed to investigate the effects of CD11b expression by
myeloblasts on clinical course and prognosis in patients with AML

Materials and
methods: Data of 123 patients diagnosed with AML between 2014-2017 in Trakya University
Faculty of Medicine, Department of Hematology, a referral tertiary hospital in Trakya
Region evaluated in a retrospective manner. Diagnosis of AML is based on WHO
2016 criteria of Myeloid Neoplasms

Results: Of the
123 patients in our study, 60 were female and 63 were male. The mean age was 57.93
years. CD11b positivity observed in 40 patients. Platelet counts were
significantly lower in patients with CD 11b positivity (p = 0.004). Likewise,
D-dimer levels at presentation were higher in CD11b positive patient group (p =
0.000). Regarding outcomes, patients with CD 11b positivity found to have lower
rates of remission with first-line remission induction therapy (p =
0.003).  There was no significant
relationship between CD-11b positivity and overall survival with Kaplan Meier
survival analysis (8.5 months in CD 11b positive group, 12.1 months in negative
group, p: 0.436).

 

Conclusion: Our
study showed that patients with CD11b expression had a lower remission rates
with remission induction chemotherapy.

Keywords

Acute Myeloid Leukemia, CD11b, Flow Cytometry

References

• 1. De Kouchkovsky I, Abdul-Hay M. 'Acute myeloid leukemia: a comprehensive review and 2016 update'. Blood Cancer J. 2016;6(7):e441. 2. Graf M, Reif S, Kroll T, Hecht K, Nuessler V, Schmetzer H. Expression of MAC-1 (CD11b) in acute myeloid leukemia (AML) is associated with an unfavorable prognosis. Am J Hematol. 2006;81(4):227-35. 3. Xu S, Li X, Zhang J, Chen J. Prognostic Value of CD11b Expression Level for Acute Myeloid Leukemia Patients: A Meta-Analysis. PLoS One. 2015;10(8):e0135981. 4. El-Sissy AH, El-Mashari MA, Bassuni WY, El-Swaayed AF. Aberrant lymphoid antigen expression in acute myeloid leukemia in Saudi Arabia. J Egypt Natl Canc Inst. 2006;18(3):244-9. 5. Shahni A, Saud M, Siddiqui S, Mukry SN. Expression of aberrant antigens in hematological malignancies: A single center experience. Pak J Med Sci. 2018;34(2):457-62. 6. Chen MH, Atenafu E, Craddock KJ, Brandwein J, Chang H. CD11b expression correlates with monosomal karyotype and predicts an extremely poor prognosis in cytogenetically unfavorable acute myeloid leukemia. Leuk Res. 2013;37(2):122-8. 7. Junca J, Garcia-Caro M, Granada I, Rodriguez-Hernandez I, Torrent A, Morgades M, et al. Correlation of CD11b and CD56 expression in adult acute myeloid leukemia with cytogenetic risk groups and prognosis. Ann Hematol. 2014;93(9):1483-9. 8. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-74. 9. McMillan SJ, Sharma RS, McKenzie EJ, Richards HE, Zhang J, Prescott A, et al. Siglec-E is a negative regulator of acute pulmonary neutrophil inflammation and suppresses CD11b beta2-integrin-dependent signaling. Blood. 2013;121(11):2084-94. 10. Wang Y, Roller J, Menger MD, Thorlacius H. Sepsis-induced leukocyte adhesion in the pulmonary microvasculature in vivo is mediated by CD11a and CD11b. Eur J Pharmacol. 2013;702(1-3):135-41. 11. Ding C, Ma Y, Chen X, Liu M, Cai Y, Hu X, et al. Integrin CD11b negatively regulates BCR signalling to maintain autoreactive B cell tolerance. Nat Commun. 2013;4:2813. 12. Ling GS, Bennett J, Woollard KJ, Szajna M, Fossati-Jimack L, Taylor PR, et al. Integrin CD11b positively regulates TLR4-induced signalling pathways in dendritic cells but not in macrophages. Nat Commun. 2014;5:3039. 13. Okita Y, Tanaka H, Ohira M, Muguruma K, Kubo N, Watanabe M, et al. Role of tumor-infiltrating CD11b+ antigen-presenting cells in the progression of gastric cancer. J Surg Res. 2014;186(1):192-200. 14. Noh H, Hu J, Wang X, Xia X, Satelli A, Li S. Immune checkpoint regulator PD-L1 expression on tumor cells by contacting CD11b positive bone marrow derived stromal cells. Cell Commun Signal. 2015;13:14. 15. Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol. 2005;33(5):523-30. 16. Marchetti M, Castoldi E, Spronk HM, van Oerle R, Balducci D, Barbui T, et al. Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood. 2008;112(10):4061-8. 17. Altieri DC, Agbanyo FR, Plescia J, Ginsberg MH, Edgington TS, Plow EF. A unique recognition site mediates the interaction of fibrinogen with the leukocyte integrin Mac-1 (CD11b/CD18). J Biol Chem. 1990;265(21):12119-22. 18. Ibrahim A, Zahran AM, Aly SS, Refaat A, Hassan MH. CD56 and CD11b Positivity with Low Smac/DIABLO Expression as Predictors of Chemoresistance in Acute Myeloid Leukaemia: Flow Cytometric Analysis. Asian Pacific Journal of Cancer Prevention. 2018;19(11):3187-92. 19. Kawai H, Tsujigiwa H, Siar CH, Nakano K, Takabatake K, Fujii M, et al. Characterization and potential roles of bone marrow-derived stromal cells in cancer development and metastasis. Int J Med Sci. 2018;15(12):1406-14. 20. Paietta E, Andersen J, Yunis J, Rowe JM, Cassileth PA, Tallman MS, et al. Acute myeloid leukaemia expressing the leucocyte integrin CD11b — a new leukaemic syndrome with poor prognosis: result of an ECOG database analysis. British Journal of Haematology. 1998;100(2):265-72. 21. Le Guyader A, Davis-Gorman G, Copeland JG, McDonagh PF. A flow cytometric method for determining the binding of coagulation factor X to monocytes in whole human blood. J Immunol Methods. 2004;292(1-2):207-15.